Affinity Asset Advisors, LLC Cyma Bay Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$12.63 - $24.47 $491,749 - $952,739	-38,935 Reduced 3.45%	1,090,441 $25.8 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $860,741 - $1.4 Million	79,258 Added 7.55%	1,129,376 $16.8 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $246,510 - $361,350	-33,000 Reduced 3.05%	1,050,118 $11.5 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $355,228 - $579,360	-60,413 Reduced 5.28%	1,083,118 $9.44 Million
Q4 2022 Feb 13, 2023	SELL	$3.22 - $6.27 $473,275 - $921,564	-146,980 Reduced 11.39%	1,143,531 $7.17 Million
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $226,400 - $347,365	-81,733 Reduced 5.96%	1,290,511 $4.52 Million
Q2 2022 Aug 12, 2022	BUY	$1.72 - $3.39 $172,000 - $339,000	100,000 Added 7.86%	1,372,244 $4.05 Million
Q1 2022 May 13, 2022	BUY	$2.77 - $3.64 $415,500 - $546,000	150,000 Added 13.37%	1,272,244 $3.96 Million
Q4 2021 Feb 11, 2022	BUY	$3.23 - $4.6 $3.62 Million - $5.16 Million	1,122,244 New	1,122,244 $3.79 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.